Physician profile
Phillip Hoffman
NPI 1154347409
$908.83
in general payments reported to CMS, 2019-2025
16 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $170 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $256.72 | 2019-2020 | |
| Lilly USA, LLC | $146.20 | 2019-2020 | |
| Spr Therapeutics, INC | $114.55 | 2025 | Sprint Pns System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $70.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.74 | 2019-2020 | |
| Amgen INC. | $32.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $24.59 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.24 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2019 | |
| Amarin Pharma, INC. | $15.89 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.88 | 2019 | |
| Genentech USA, INC. | $11.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.50 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.